EDGAR Online

VIROPHARMA INC

Reported by

BAKER BIOTECH CAPITAL (GP), LLC

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 08/25/11 for the Period Ending 08/23/11

Address	730 STOCKTON DRIVE EXTON, PA 19341
Telephone	6104587300
CIK	0000946840
Symbol	VPHM
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

Powered By EDGAR Online
http://www.edgar-online.com
© Copyright 2011, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Baker Biotech Capital (GP), LLC	**VIROPHARMA INC [VPHM]**	
(Last) (First) (Middle) **667 MADISON AVENUE, 21ST FLOOR**	3. Date of Earliest Transaction (MM/DD/YYYY) **8/23/2011**	____ Director __ **X** __ 10% Owner ____ Officer (give title below) ____ Other (specify below)
(Street) **NEW YORK, NY US 10065** (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ **X** _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock (1) (2)	**8/23/2011**		**P**		**5468**	**A**	**$16.9741**	**1770681**	**I**	**Through Partnership** (3)

Table II - Derivative Securities Beneficially Owned (*e.g.* , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

(1) In addition to Baker Biotech Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as Baker Biotech Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were members of a group of such shareholders. (Continued in footnote 2).

(2) However, the Reporting Persons do not affirm that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them does not affirm beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.

(3) Represents securities beneficially owned by (i) 667, L.P., the sole general partner of which is Baker Biotech Capital, L.P. (the "General Partner"), a limited partnership the sole general partner of which is Baker Biotech Capital (GP),LLC., (ii) FBB Associates, and (iii) certain accounts managed by the General Partner. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC and the sole partners of FBB Associates.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Baker Biotech Capital (GP), LLC **667 MADISON AVENUE, 21ST FLOOR** **NEW YORK, NY US 10065**		**X**		
BAKER JULIAN **667 MADISON AVENUE, 21ST FLOOR** **NEW YORK, NY US 10065**		**X**		
BAKER FELIX **667 MADISON AVENUE, 21ST FLOOR** **NEW YORK, NY US 10065**		**X**		

Signatures

/s/ Julian C. Baker, as Managing Member of Baker Biotech Capital (GP), LLC	**8/25/2011**
** Signature of Reporting Person	Date
/s/ Julian C. Baker	**8/25/2011**
** Signature of Reporting Person	Date
/s/ Felix J. Baker	**8/25/2011**
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

***** If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.